Cargando…

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide) is an anti-tumour agent that has a highly selective toxicity to hypoxic cells. In this study we delineate the role of several different bioreductive enzymes in the metabolism of SR 4233 by two tumour cell lines HT 1080 (human fibrosarcoma) and SCCVII...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, J., Biedermann, K. A., Wolf, C. R., Brown, J. M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968170/ https://www.ncbi.nlm.nih.gov/pubmed/8431360

Ejemplares similares

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995)

SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.
por: Biedermann, K. A., et al.
Publicado: (1991)

The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
por: Keohane, A., et al.
Publicado: (1990)

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
por: Brown, J. M.
Publicado: (1993)

Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
por: Minchinton, A. I., et al.
Publicado: (1992)

The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
por: Lartigau, E., et al.
Publicado: (1996)

The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
por: Skarsgard, L. D., et al.
Publicado: (1993)

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
por: Chinje, E C, et al.
Publicado: (1999)

Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.
por: Silva, J. M., et al.
Publicado: (1993)

Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990)

Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
por: Khan, S., et al.
Publicado: (1995)

The penetration of cytotoxins into malignant tumours.
por: Rowe-Jones, D. C.
Publicado: (1968)

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
por: Patterson, A. V., et al.
Publicado: (1997)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
por: Patterson, L H, et al.
Publicado: (2000)

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997)

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
por: Saunders, M P, et al.
Publicado: (2000)

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
por: Doherty, G. P., et al.
Publicado: (1998)

Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs.
por: Siim, B. G., et al.
Publicado: (1994)

Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation
por: Janssens, M Y, et al.
Publicado: (1999)

Bioreduction: the biological activity, characterization, and synthesis of silver
por: KORKMAZ, Nesrin
Publicado: (2020)

Anti-tumour cytotoxin produced by human monocytes: studies on its mode of action.
por: Matthews, N.
Publicado: (1983)

Escherichia coli Subtilase Cytotoxin
por: Paton, Adrienne W., et al.
Publicado: (2010)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021)

Metagenomic ene-reductases for the bioreduction of sterically challenging enones
por: Dobrijevic, Dragana, et al.
Publicado: (2019)

Helicobacter pylori infection: is there circulating vacuolating cytotoxin A or cytotoxin-associated gene A protein?
por: Imoto, Ichiro, et al.
Publicado: (2022)

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2001)

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2002)

Influence of Culture Conditions on the Bioreduction of Organic Acids to Alcohols by Thermoanaerobacter pseudoethanolicus
por: Scully, Sean Michael, et al.
Publicado: (2021)

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
por: McKeage, Mark J, et al.
Publicado: (2012)

Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.
por: Hodgkiss, R. J., et al.
Publicado: (1995)

A NOTE ON THE SPECIFICITY OF CYTOTOXINS
por: Lambert, Robert A.
Publicado: (1914)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Stereoselective Bioreduction of α-diazo-β-keto Esters
por: González-Granda, Sergio, et al.
Publicado: (2020)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines
por: Kostrzewa-Nowak, D, et al.
Publicado: (2005)

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
por: Olive, P. L.
Publicado: (1995)

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
por: Hejmadi, M. V., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_afeug225tqt3oh834qojkaa53p